---
title: "Wanchen Biotechnology: Third quarter net profit attributable to shareholders was 383 million yuan, a year-on-year increase of 361.22%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/262012521.md"
description: "36Kr learned that Wanchen Biotechnology released its third-quarter financial report. The report shows that in the third quarter, the company achieved operating revenue of 13.98 billion yuan, a year-on-year increase of 44.15%; the net profit attributable to shareholders of the listed company was 383 million yuan, a year-on-year increase of 361.22%; basic earnings per share were 2.0436 yuan"
datetime: "2025-10-21T09:06:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262012521.md)
  - [en](https://longbridge.com/en/news/262012521.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262012521.md)
---

# Wanchen Biotechnology: Third quarter net profit attributable to shareholders was 383 million yuan, a year-on-year increase of 361.22%

36Kr learned that Wanchen Biotechnology released its third-quarter financial report. The report shows that in the third quarter, the company achieved operating revenue of 13.98 billion yuan, a year-on-year increase of 44.15%; the net profit attributable to shareholders of the listed company was 383 million yuan, a year-on-year increase of 361.22%; basic earnings per share were 2.0436 yuan

### Related Stocks

- [300972.CN](https://longbridge.com/en/quote/300972.CN.md)

## Related News & Research

- [Phase 3-ready cancer biotech Parabilis Medicines files for a $100 million IPO](https://longbridge.com/en/news/286972125.md)
- [New York Governor Signs Bills To Preserve Mandatory Vaccines](https://longbridge.com/en/news/286947583.md)
- [Microbiotica reports positive results for MB097 in advanced melanoma](https://longbridge.com/en/news/286740265.md)
- [09:35 ETOpen Medicine Launches Ahead of ASCO, Introducing "Living Algorithms" for Real-Time Oncology Decision-Making](https://longbridge.com/en/news/286923155.md)
- [Israel-based Phase 3 ocular diseases biotech Tarsier Pharma sets terms for $45 million US IPO](https://longbridge.com/en/news/286793435.md)